News

Hemanext successfully closes Series A equity funding round

Hemanext Inc., a leading innovator in blood processing and storage technology, today announced that it has successfully closed its Series A fundraising round, raising $15m from both existing and new investors. The company has now raised more than $100 million since its founding.

Major global investors in this round include Omega Family Office, Antaeus Enterprises, Inc., The Testa Family Office, Grabe Family Office, The Eduardo Avayu Family Office, and Stephen Eckert, President, The Classic Group, along with investors from other top global family offices, private equity firms, investment banks, and law firms. To accommodate continuing strong investor interest, the company may accept up to an additional $15m in the current round.

“Hemanext is leading a ground-breaking initiative aiming to improve the quality of red blood cells, a critical element of modern medicine, and one of the largest markets in healthcare,” said Martin Cannon, Co-Founder and CEO of Hemanext. “We are gratified by the tremendous response we have received from leading private investors in the U.S. and Europe who believe in the potential of our cutting-edge technology which has the potential to improve outcomes for millions of patients worldwide. Our rollout in Europe following receipt of CE Mark certification continues on track, and I am very grateful to our Board, investors, advisors, and, of course, to the extraordinarily talented engineers and physicians driving our progress.”

The Potential to Revolutionize Blood Processing and Storage

The processing and storage of blood for transfusion is fundamental to healthcare, and over 90 million units of red blood cells are transfused worldwide annually.1

The innovative Hemanext ONE® RBC Processing and Storage System is a medical device designed to process and store eligible Red Blood Cells [see below for specific CE Marking intended purpose]. The company’s aim is to significantly improve the quality of stored red blood cell (RBCs) by limiting oxygen and carbon dioxide levels in the storage environment. Preclinical data has shown that this medical device can maintain RBCs at or below 20% oxygen saturation for up 42 days2, thereby creating hypoxic RBCs.

Clinicians believe that limiting oxygen—the main driver of RBC damage—could have a meaningful impact on healthcare outcomes for the 4-5 million American patients transfused annually3. The Hemanext technology has the potential to revolutionize how blood centers approach RBC processing and storage while simultaneously alleviating shortages in the global blood supply.

Hemanext strives to provide blood centers with a technology that fosters a decrease in RBC transfusion frequency and a reduction in volume by up to 50%, as shown in preclinical data.4 This reduction has potential to limit associated side effects and the need for therapies to treat them.

Hypoxic blood has the potential to benefit millions of patients with chronic conditions requiring ongoing blood transfusions, including thalassemia, sickle cell disease (SCD), and myelodysplastic syndromes (MDS), as well as patients needing massive transfusions during surgery, trauma, and other medical procedures.

Product CE marked for Sale in Europe; Preparation has Begun for Q4 FDA Submission

On April 13, 2021, Hemanext announced that it had received CE Mark certification for Hemanext ONE, clearing the way for the innovative medical device to be sold in European markets. Studies are underway to measure the impact of hypoxic RBCs on patient outcomes and the potential cost savings.

The company is preparing for a Q4 submission of its FDA application for US market authorization. In the U.S., the Hemanext ONE device remains available for investigational use only.

Series A and B Equity Rounds

Hemanext continues to be in discussions with additional potential A round investors, including institutions, who may close investments before the end of the year. The company expects to launch its B round of financing in the first half of 2022.

Sonenshine Fulford Group, a collaboration between Sonenshine Partners in the US and The Fulford Group in the UK, is advising Hemanext in its fund-raising.

About Hemanext

Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company’s research and development efforts center on the study of hypoxically stored red blood cells (RBCs). The company’s aim is to significantly improve the quality of stored RBCs by limiting oxygen and carbon dioxide levels in the storage environment.

Since its founding in 2008, Hemanext has envisioned a world with fewer and better transfusions. In its early years, multiple grants from the U.S. National Institutes of Health (NIH) enabled the company to demonstrate the feasibility of hypoxic RBC storage, develop its first prototype system, and conduct in vivo research. To date, the company has raised more than $100 million.

On April 13, 2021, Hemanext announced that it had received CE Mark certification for Hemanext ONE, clearing the way for the medical device to be sold in European markets.

In the EU, the system is CE Marked for the processing and storage CPD/PAGGSM Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared and processed with the HEMANEXT ONE system within 24-hours of collection. The HEMANEXT ONE system limits the O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2/CO2 Reduced may be stored for up to 42 days at 1-6°C. HEMANEXT ONE is used for volumes no greater than 350 ml of LR RBC.5

In the United States, the company is preparing for a Q4 submission of its FDA application for U.S. market authorization; the product remains available for investigational use only in the U.S.

Preclinical data show that the medical device can maintain RBCs at or below 20% oxygen saturation for up to 42 days2, thereby creating hypoxic RBCs. Clinical studies are underway to measure the impact of hypoxic RBCs on patient outcomes and the potential cost savings.

Hemanext Media Contact
Nathan Riggs / Shea Maney
nathan.riggs@kekstcnc.com / Shea.Maney@kekstcnc.com

Stacy Smith
Associate Director Marketing Communications
stacy.smith@hemanext.com

  1. Flegel WA, Br J Haematol. 2014;165(1):3-16. doi:10.1111/bjh.12747
  2. Brouard, D et al. Vox Sang 2018; 113: 153.2018.
  3. Yoshida, T et al. Blood Transfus. 2019: 17 (1): 27-52.
  4. Williams, A et al. Shock. 2020: 53(3): 352-362.
  5. Hemanext ONE, Instructions for Use for the European Union (April 2021), DOF
Next

By producing higher quality RBCs, the Hemanext ONE system has the potential to enable fewer and more effective transfusions for patients. I am truly excited by the possibility of bringing this improved red blood cell replacement therapy to populations in the U.S. that have been waiting for a transformative technology like this one.

Dr. Philip C. Spinella
Professor, Department of Surgery and Department of Critical Care Medicine at University of Pittsburgh

We value our partnership with Hemanext to enhance blood product quality and availability. Hemanext ONE has the potential to strengthen the resiliency of the blood supply, and this FDA authorization is a significant milestone to that end.

Ralph Vassallo, MD, FACP
Executive Vice President, Chief Medical and Scientific Officer of Vitalant

The Hemanext ONE system offers promise to improve the treatment landscape for patients burdened by transfusions and could be an essential step towards performing fewer and better transfusions. Having long championed Hemanext’s transformative initiatives, I eagerly anticipate witnessing the positive influence, right here in the United States, on the advancement of transfusion therapy quality.

Paul M. Ness, MD
Former Director, Division of Transfusion Medicine at Johns Hopkins University and board member of Hemanext

By deoxygenating red cells and maintaining them in their hypoxic state throughout storage, the resulting red cells experience less oxidative stress and oxidative damage, have improved metabolism, and are also more deformable leading to improved micro vascular profusion and less hemolysis.

Dr. Steven Spitalnik, MD
Co-Director of the Laboratory of Transfusion Biology, Colombia University

The preclinical data by Williams et al. show anaerobically stored RBCs achieve multiple clinically important functional resuscitation goals, with a smaller volume of fluid and the FDA benchmark of 24-hour RBC recovery. I look forward to the clinical trials in bleeding patients.

John Holcomb, MD, FACS
University of Alabama at Birmingham

I have had several patients who have received Hemanext hypoxic blood, and several of the patients have personally said thanks for having been given the opportunity and also that they have felt better after transfusion with hypoxic blood compared to conventional transfusion. One must of course be careful not to attach too much importance to such observations, but I would still like to mention that there has been a remarkable tendency towards this.

Håkon Reikvam, MD, PhD
Professor, Department of Clinical Science, University of Bergen, Norway

CONTACT US  |  TERMS OF USE

PRIVACY & COOKIES POLICY

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2026 Hemanext, Inc. All rights reserved.

Contact Us